Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Other Non-Current Assets (2016 - 2025)

Tandem Diabetes Care's Other Non-Current Assets history spans 13 years, with the latest figure at $22.9 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 342.62% year-over-year to $22.9 million; the TTM value through Dec 2025 reached $22.9 million, up 342.62%, while the annual FY2025 figure was $22.9 million, 342.62% up from the prior year.
  • Other Non-Current Assets reached $22.9 million in Q4 2025 per TNDM's latest filing, up from $16.5 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $40.3 million in Q4 2023 to a low of $5.2 million in Q4 2024.
  • Average Other Non-Current Assets over 5 years is $20.5 million, with a median of $16.7 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: surged 388.37% in 2021, then crashed 87.19% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $15.7 million in 2021, then surged by 50.25% to $23.6 million in 2022, then soared by 70.69% to $40.3 million in 2023, then plummeted by 87.19% to $5.2 million in 2024, then surged by 342.62% to $22.9 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Other Non-Current Assets are $22.9 million (Q4 2025), $16.5 million (Q3 2025), and $17.3 million (Q2 2025).